Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin + EGFR-TKIs in EGFR-mutant NSCLC
NCT02321293Phase 1Unknown
- Sponsor
- Lady Davis Institute for Medical Research
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Lady Davis Institute for Medical Research. Primary endpoints: Feasibility assessed by Willingness of patients to participate at 8 weeks, Feasibility assessed by follow-up rate at 8 weeks and 3 more. Status: unknown.
Beyond the preview
Go deeper on NCT02321293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321293.